Motus GI (NASDAQ:MOTS – Get Free Report) and Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Risk & Volatility
Motus GI has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500.
Valuation & Earnings
This table compares Motus GI and Lyra Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Motus GI | $319,000.00 | 0.45 | -$12.87 million | ($15.64) | 0.00 |
| Lyra Therapeutics | $1.82 million | 8.05 | -$62.68 million | ($1.20) | -0.20 |
Profitability
This table compares Motus GI and Lyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Motus GI | -3,239.75% | -1,731.08% | -115.99% |
| Lyra Therapeutics | -5,570.88% | -102.22% | -57.77% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Motus GI and Lyra Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Motus GI | 0 | 0 | 0 | 0 | N/A |
| Lyra Therapeutics | 1 | 4 | 1 | 0 | 2.00 |
Lyra Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 1,773.44%. Given Lyra Therapeutics’ higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Motus GI.
Institutional & Insider Ownership
20.1% of Motus GI shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 0.3% of Motus GI shares are owned by insiders. Comparatively, 17.4% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Lyra Therapeutics beats Motus GI on 9 of the 13 factors compared between the two stocks.
About Motus GI
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.
